GKOS übertreffen die 28 der letzten 40Schätzungen.
70%
Nächster Bericht
Datum des nächsten Berichts
18. Feb. 2026
Estimate forQ4 25(Revenue/ EPS)
$132.09M
/
-$0.21
Implizierte Änderung vonQ3 25(Revenue/ EPS)
-1.09%
/
+31.25%
Implizierte Änderung vonQ4 24(Revenue/ EPS)
+25.20%
/
-47.50%
Glaukos Corporation earnings per share and revenue
On 29. Okt. 2025, GKOS reported earnings of -0.16 USD per share (EPS) for Q3 25, beating the estimate of -0.26 USD, resulting in a 39.14% surprise. Revenue reached 133.54 million, compared to an expected 124.99 million, with a 6.84% difference. The market reacted with a +13.89% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 18 analysts forecast an EPS of -0.21 USD, with revenue projected to reach 132.09 million USD, implying an increase of 31.25% EPS, and decrease of -1.09% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AngioDynamics, Inc.
Report Date
06. Jan. 2026 For Q2 26
Estimate
-$0.10
Aktuell
$0.00
Überraschung
+100.00%
FAQ
What were Glaukos Corporation's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Glaukos Corporation reported EPS of -$0.16, beating estimates by 39.14%, and revenue of $133.54M, 6.84% above expectations.
How did the market react to Glaukos Corporation's Q3 2025 earnings?
The stock price moved up 13.89%, changed from $77.09 before the earnings release to $87.80 the day after.
When is Glaukos Corporation expected to report next?
The next earning report is scheduled for 18. Feb. 2026.
What are the forecasts for Glaukos Corporation's next earnings report?
Based on 18
analysts, Glaukos Corporation is expected to report EPS of -$0.21 and revenue of $132.09M for Q4 2025.